文献速递耳科与耳神经小儿耳鼻咽喉

遗传性听力损失的单基因与多基因检测:商业保险队列中的使用与费用

Single Versus Multigene Testing for Hereditary Hearing Loss: Use and Costs in a Commercially Insured Cohort.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-01-22

该回顾性研究利用2015至2020年Optum Data Mart保险索赔数据,分析儿童遗传性听力损失基因检测的使用趋势与费用。在91,986名接受任何基因检测的儿童中,601名(0.65%)接受了听力相关检测。单基因GJB2/6检测比例随时间保持相似,而多基因听力损失面板使用增加,其费用下降。

要点

  • 2015至2020年,91,986名儿童接受基因检测,其中601名(0.65%)为听力相关检测。
  • 单基因GJB2/6检测比例年均变化为-1.3%(95%CI:-4.3%,1.7%),多基因HLP年均变化为4.0%(95%CI:0.4%,7.5%)。
  • 单基因GJB2/6检测中位费用年均变化为-$34(95%CI:-$86,$18),多基因HLP为-$145(95%CI:-$278,-$12)。

核心结论

  • 相较于GJB2/6分子检测,多基因听力损失面板在遗传性听力损失中应用越来越普遍。
  • 多基因听力损失面板的全面性及费用下降为其更广泛采用提供了依据。

研究设计与样本

  • 研究设计为回顾性研究,使用保险索赔数据。
  • 数据来源为Optum Data Mart数据库,时间范围为2015年至2020年。
  • 研究纳入91,986名接受任何适应症基因检测的儿童。

主要发现

  • 2015年至2020年,91,986名儿童接受任何适应症基因检测,其中601名(0.65%)接受了听力特异性检测。
  • 单基因GJB2/6检测比例随时间保持相似,年均变化为-1.3%(95%CI:-4.3%,1.7%)。
  • 多基因听力损失面板使用随时间增加,年均变化为4.0%(95%CI:0.4%,7.5%)。
  • 单基因GJB2/6检测的中位费用在研究期间保持恒定,年均变化为-$34(95%CI:-$86,$18)。
  • 多基因听力损失面板的中位费用在研究期间下降,年均变化为-$145(95%CI:-$278,-$12)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objectives of this study were to describe trends in single-gene GJB2/6 (connexin 26/30) and multigene hearing loss panel (HLP) testing for hereditary hearing loss using real-world evidence. STUDY DESIGN: Retrospective study using insurance claims data. SETTING: Optum Data Mart database from 2015 to 2020. METHODS: Rates of overall and hearing-specific genetic testing and costs to insurers and patients were reported. Linear regression models were used to assess the proportion of single-gene GJB2/6 testing over time. Additional linear regression models were used to assess changes in costs over time. RESULTS: From 2015 to 2020, 91,986 children received genetic testing for any indication, of which 601 (0.65%) received hearing-specific tests. The proportion of single-gene GJB2/6 testing remained similar over time (mean difference [MD]: -1.3% per year; 95% confidence interval [CI]: -4.3%, 1.7%), while multigene HLP use increased over time (MD: 4.0% per year; 95% CI: 0.4%, 7.5%). The median charge for single-gene GJB2/6 testing remained constant during the study period (MD: -$34; 95% CI: -$86, $18), while the median charge for multigene HLP decreased during the study period (MD: -$145 per year; 95% CI: -$278, -$12). CONCLUSION: Compared to molecular testing for GJB2/6, HLPs are becoming more common for hereditary hearing loss. The comprehensiveness of HLP and decreasing costs provide justification for its more widespread adoption moving forward.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Moon PK, Qian ZJ, Stevenson DA, et al. Single Versus Multigene Testing for Hereditary Hearing Loss: Use and Costs in a Commercially Insured Cohort. Otolaryngol Head Neck Surg. 2023. PMID: 36939467. doi:10.1002/ohn.204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。